MAP3K19

Across TCGA pan-cancer cohorts, MAP3K19 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated MAP3K19 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MAP3K19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP3K19 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

THYM, UCEC, and LUSC are the cancer types where MAP3K19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	II,III,IV	0.948	0.425	.004	34	view →
LUSC	DFS	Median	All	0.937	0.645	.002	15	view →
KIRP	OS	Median	II,III,IV	0.188	0.751	.002	12	view →
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.025	0.775	<.001	6	view →
SKCM	OS	Median	III,IV	0.478	0.751	.019	5	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.112	0.544	.042	3	view →
SCLC	DFS	Median	All	1.000	0.531	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MAP3K19–THYM (OS)

Open the THYM breakdown →